AST or ALT elevations occurred more frequently in the neratinib arm compared to the placebo arm of Study 3004. Elevations of AST or ALT > 10 x ULN and > 20 x ULN occurred in few patients overall, although numerically more in neratinib-treated than placebo-treated patients. There have been no cases of drug induced liver injury associated with neratinib.